Fig. 5
From: A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism
CAD-31 reduces markers for inflammation in hippocampal tissue. a Vascular cell adhesion molecule (VCAM). b Clusterin. c Receptor for advanced glycation endproducts (RAGE). d Radioimmunoprecipitation assay (RIPA) insoluble proteins. *** p < 0.001; * p < 0.05; n = 6 per group. GAPDH Glyceraldehyde 3-phosphate dehydrogenase, C + 31 CAD-31-treated control mice, AD + 31 CAD-31-treated Alzheimer’s disease APPswe/PS1∆E9 mice, MW Molecular weight